✦ LIBER ✦

New clinical evidence from the European tobramycin trial in cystic fibrosis

✍ Scribed by M.E Hodson; C.G Gallagher

Book ID: 118640054
Publisher: Elsevier Science
Year: 2002
Tongue: English
Weight: 81 KB
Volume: 1
Category: Article
ISSN: 1569-1993
DOI: 10.1016/s1569-1993(02)00004-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Insights into cystic fibrosis microbiolo

Insights into cystic fibrosis microbiology from the European tobramycin trial in cystic fibrosis

✍ J.R.W. Govan 📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 93 KB

Guideline on the design and conduct of c

Guideline on the design and conduct of cystic fibrosis clinical trials: The European Cystic Fibrosis Society–Clinical Trials Network (ECFS-CTN)

✍ K. De Boeck; V. Bulteel; H. Tiddens; T. Wagner; I. Fajac; S. Conway; F. Dufour; 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 570 KB

Lung clearance index: Evidence for use i

Lung clearance index: Evidence for use in clinical trials in cystic fibrosis

✍ Kent, L.; Reix, P.; Innes, J.A.; Zielen, S.; Le Bourgeois, M.; Braggion, C.; Lev 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 334 KB

Tobramycin inhalation powder manufacture

Tobramycin inhalation powder manufactured by improved process in cystic fibrosis: the randomized EDIT trial

✍ Galeva, Ivanka; Konstan, Michael W.; Higgins, Mark; Angyalosi, Gerhild; Brockhau 📂 Article 📅 2013 🏛 Informa plc 🌐 English ⚖ 287 KB

Safety, efficacy and convenience of tobr

Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial

✍ Michael W. Konstan; Patrick A. Flume; Matthias Kappler; Raphaël Chiron; Mark Hig 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 290 KB

Systematic review of the dry powder inha

Systematic review of the dry powder inhalers colistimethate sodium and tobramycin in cystic fibrosis

✍ Uttley, L.; Harnan, S.; Cantrell, A.; Taylor, C.; Walshaw, M.; Brownlee, K.; Tap 📂 Article 📅 2013 🏛 European Respiratory Society 🌐 English ⚖ 427 KB

This systematic review evaluated evidence for two dry powder formulations, colistimethate sodium and tobramycin, for the treatment of chronic __Pseudomonas aeruginosa__ in cystic fibrosis, as part of the UK national recommendation process for new technologies. Electronic bibliographic databases were